4D Pharma PLC (DDDD) 2019年年度报告「LSE」.pdf

1、4D pharma plc Annual Report and Accounts 2019Leading the development of LiveBiotherapeuticsWhat we do4D was established with the mission of leveraging the deep and varied interactions between the human body and the gut microbiome the trillions of bacteria that colonise the human gastrointestinal tra

2、ct to develop an entirely novel class of drug:Live Biotherapeutics.We are focussed on understanding how individual strains of bacteria function and how their interactions with the human host can be exploited to treat particular diseases,from cancer to asthma to conditions of the central nervous syst

3、em.Pioneering a revolutionary classofmedicines:LiveBiotherapeutic Follow us on LinkedIn4D pharma plc Annual Report and Accounts 20191StrategicGovernanceFinancial HighlightsOperational highlights First-in-class data in oncology positive safety and preliminary clinical observations of lead immuno-onco

4、logy candidate MRx0518 in combination with Keytruda Entered a research collaboration and option agreement with MSD to use the MicroRx discovery platform to develop Live Biotherapeutics in the vaccines space,including an upfront payment and potential milestone payments totalling$1 billion MSD collabo

5、ration included commitment to equity investment in 4D by MSD,triggered after period end Launched a Phase I/II trial of MRx-4DP0004 in partly controlled asthma thefirst clinical trial of a single strain Live Biotherapeutic in this indication Expanded our Board of Directors,adding clinical and commerc

6、ial expertise from both Europe and US Since the period end In early January 2020 we launched our third trial of MRx0518,in pancreatic cancer in combination with radiotherapy In February 2020 4D completed a placing and subscription raising gross proceeds of 22 million In April 2020 we announced inter